"Walking around with this very visible, very robust ailment has a pretty tremendous impact on your mental health," Maddox Patt tells PEOPLE ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...

For people with chronic skin conditions, telehealth altered how they care for their skin and their bodies by removing ...

J&J’s Icotyde will take on AbbVie’s blockbuster injectable Skyrizi as analysts forecast a blockbuster future for the pill.

Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the year ended ...

Wendy Smith Begolka, MBS, shares strategies to better meet the needs of patients with chronic inflammatory skin diseases.

A >500-patient, randomized, double-blind phase 3 trial showed CT-P43 achieved PASI 75 equivalence at week 12 versus ustekinumab under standard induction and q12w maintenance dosing. Durability through ...

Spread the loveAs the pharmaceutical industry continues to evolve, staying updated on significant advancements and market trends is crucial for marketers. March 19, 2026, brings pivotal updates that ...

Johnson & Johnson's novel oral peptide ICOTYDE wins FDA approval for plaque psoriasis, offering a convenient alternative to injectables with strong clinical results and major sales potential.

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

Oral icotrokinra is now FDA-approved for plaque psoriasis, offering a new systemic option for adults and adolescents who weigh at least 40kg.

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic ...